-

MindMed to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.

About MindMed

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health.

MindMed trades on NASDAQ under the symbol MNMD.

Contacts

Investors:
Gitanjali Jain
VP, Head of Investor Relations
ir@mindmed.co

Media:
media@mindmed.co

Mind Medicine (MindMed) Inc.

NASDAQ:MNMD

Release Versions

Contacts

Investors:
Gitanjali Jain
VP, Head of Investor Relations
ir@mindmed.co

Media:
media@mindmed.co

More News From Mind Medicine (MindMed) Inc.

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that Rob Barrow, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT. “It is a privilege to participate in the J.P. Morgan Healthcare Conference as we continue to...

MindMed Announces New Employee Inducement Grant

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 31,500 common shares of the Company (the "Options") with an effective grant date of December 15, 2025. The Options have an exercise price...

MindMed Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 182,100 common shares of the Company (the “Options”) with effective grant dates of November 17, 2025, November 24, 2025 and December 1, 2...
Back to Newsroom